MYOV Myovant Sciences Ltd.

12.78
+0.26  (+2%)
Previous Close 12.52
Open 12.52
Price To Book 19.36
Market Cap 904984274
Shares 70,812,541
Volume 65,628
Short Ratio 11.98
Av. Daily Volume 148,153

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data 1Q 2020.
Relugolix - SPIRIT 1
Endometriosis-associated pain
Phase 3 data 1Q 2020.
Relugolix - SPIRIT 2
Endometriosis-associated pain
Phase 3 data due 4Q 2019.
Relugolix - HERO
Advanced prostate cancer
Phase 3 LIBERTY 1 top-line data met primary endpoint - May 14, 2019. LIBERTY 2 data due 3Q 2019.
Relugolix - LIBERTY 1 and LIBERTY 2
Menstrual bleeding associated with uterine fibroids

Latest News

  1. Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea
  2. Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates
  3. Myovant Shares Slide Despite Positive Late-Stage Data For Menstrual Bleeding Drug
  4. Myovant stock up 1.6% after Phase 3 trial meets endpoints
  5. Myovant Sciences' uterine fibroids combo therapy meets main goal in study
  6. Introducing Myovant Sciences (NYSE:MYOV), The Stock That Dropped 23% In The Last Year
  7. Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
  8. Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
  9. Here’s What Hedge Funds Think About Myovant Sciences Ltd. (MYOV)
  10. Myovant Sciences to Present at Upcoming Investor Conferences
  11. Myovant- "Value Creation" in Cancer Treatment
  12. 4 Disruptive Healthcare Stocks You've Never Heard Of
  13. Myovant Sciences: Fiscal 3Q Earnings Snapshot
  14. Myovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018
  15. Andreas Halvorsen Plunges Into Biotech Company Myovant Sciences
  16. Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
  17. Myovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
  18. Myovant Sciences to Participate in Two Upcoming Investor Conferences
  19. Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences — Renewed Outlook, Key Drivers of Growth
  20. Myovant Provides Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2018